2022
The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma
Talia K, Banet N, Buza N. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology 2022, 55: 8-18. PMID: 36503635, DOI: 10.1016/j.pathol.2022.11.004.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Uterine serous carcinomaRole of HER2Serous carcinomaClinical trialsHER2 overexpressionPrognostic biomarkerTherapeutic targetHigh-grade endometrioid carcinomaEpidermal growth factor receptor 2Vulvar Paget's diseaseGrowth factor receptor 2Time of diagnosisFuture clinical trialsGynaecological cancer careClinical trial dataHER2 protein overexpressionFactor receptor 2P53 mutant tumorsRecurrent diseaseSurvival benefitGynaecological malignanciesPaget's diseaseClinical benefitEndometrial carcinoma
2018
Intra‐operative evaluation of prophylactic hysterectomy and salpingo‐oophorectomy specimens in hereditary gynaecological cancer syndromes
Wong S, Ratner E, Buza N. Intra‐operative evaluation of prophylactic hysterectomy and salpingo‐oophorectomy specimens in hereditary gynaecological cancer syndromes. Histopathology 2018, 73: 109-123. PMID: 29484698, DOI: 10.1111/his.13503.Peer-Reviewed Original ResearchConceptsIntra-operative evaluationTotal hysterectomyLynch syndromePermanent sectionsSalpingo-oophorectomy specimensFrozen section diagnosisGermline BRCA 1BrCa casesOccult malignancySurgical stagingProphylactic hysterectomyGynaecological malignanciesFinal diagnosisSecond surgeryGross findingsRetrospective analysisBRCA-1Cancer syndromesGross lesionsSection diagnosisDiagnostic discrepanciesFrozen sectionsMalignancyPractice recommendationsLS cases